Role of p53 mutations in the radiosensitivity status of tumor cells

Tumori

Volumn 84, Issue 5, 1998, Pages 517-520

  Chiarugi, Vincenzo ^a   Magnelli, Lucia ^a   Cinelli, Marina ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Mutations; p53; Radiosensitivity

Indexed keywords

PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

APOPTOSIS; CELL CYCLE; CELL DEATH; DNA DAMAGE; DNA REPAIR; GENE MUTATION; IONIZING RADIATION; RADIOSENSITIVITY; REVIEW; TRANSCRIPTION REGULATION; TUMOR CELL CULTURE;

EID: 0031672216     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089169808400501     Document Type: Review

References (32)

1. Aloni-Grinstein R., Schwartz D., Rotter V.: Accumulation of wild-type p53 protein upon gamma-irradiation induces a G2 arrest-dependent immunoglobulin Kappa light chain gene expression. EMBO J., 14: 1392-1401, 1995.
2. Bergh J., Norberg T., Siogren S., Lindgren A., Holmberg L.: p53 mutations leading to radioresistance. Nature Med., 1: 1029-1034, 1995.
3. Clarke A.R., Purdie C.A., Harrison D.J., Morris R.G., Bird C.C., Hooper M.L., Wyllie A.H.: Thymocyte apoptosis induced by p53-dependent and -independent pathways. Nature, 362: 849-852, 1993.
4. Cote R.J., Esrig D., Groshen S., Jones P.A., Skinner D.G.: p53 and treatment of bladder cancer. Nature, 385: 123-125, 1997.
5. Delphin C., Baudier J.: The protein kinase C activator, phorbol ester, cooperates with the wild-type p53 species of ras-transformed embryo fibroblasts growth arrest. J. Biol. Chem., 269: 29579-29587, 1994.
6. Deppert W.: The yin and yang of p53 in cellular proliferation. Semin. Cancer Biol., 5: 187-202, 1994.
7. El-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parson R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., Vogelstein B.: WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
8. Gallagher W.M., Cairney M., Schott B., Roninson I.B., Brown R.: Identification of p53 genetic suppressor elements which confer resistance to cisplatin. Oncogene, 14: 185-193, 1997.
9. Gallardo D., Drazan K.E., McBride W.H.: Adenovirus-based transfer of wild-type p53 gene increases ovarian tumor radiosensitivity. Cancer Res., 56: 4891-4893, 1996.
10. Gu W., Roeder R.G.: Activation of p53 sequence specific DNA binding by acetylation of p53 C-terminal domain. Cell, 90: 595-606, 1997.
11. Harris C.C.: Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J. Natl. Cancer. Inst., 88: 1442-1453, 1996.
12. Hupp T.R., Meek D.W., Midgley C.A., Lane D.P.: Regulation of the specific DNA binding function of p53. Cell, 71: 875-886, 1992.
13. Hupp T.R., Sparks A., Lane D.P.: Small peptides activate the latent sequence-specific DNA binding function of p53. Cell, 80: 237-245, 1995.
14. Kastan M.B., Onyekwere O., Sidransky D., Vogelstein B., Craig R.W.: Participation of the p53 protein in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991.
15. Kaufmann W.K., Paules R.S.: DNA damage and cell cycle checkpoints. FASEB J., 10: 238-247, 1996.
16. Kieser A., Weich H.A., Brandner G., Marme D., Kolch W.: Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene, 9: 963-969, 1994.
17. Lane D.P.: The regulation of p53 function: Steiner Award Lecture. Int. J. Cancer, 57: 623-627, 1994.
18. Lee J.M., Bernstein A.: Apoptosis, cancer and the p53 tumor suppressor gene. Cancer Metastasis Rev., 14: 149-161, 1995.
19. Lowe S.W., Jacks T.: Reply to the Cote et al. article. Nature, 385: 124-124, 1997.
20. Lowe S.W., Ruley H.E., Jacks T., Housman D.E.: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957-967, 1993.
21. Margulies L., Sehgal P.B.: Modulation of the human interleukin-6 promoter (IL-6) and transcription factor C/EBP beta (NF-IL6) activity by p53 species. J. Biol. Chem., 268: 15096-15100, 1993.
22. Miyashita T., Krajewsky S., Krajewska M., Wang H.G., Lin H.K., Liebermann D.A., Hoffman B., Reed J.C.: Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene, 9: 1799-1805, 1994.
23. Muller B.F., Paulsen D., Deppert W.: Specific binding of MAR/SAR elements by mutant p53. Oncogene, 12: 1941-1952, 1996.
24. Nelson W.G., Kastan M.B.: Participation of p53 protein in cellular response to DNA damage. Mol. Cell. Biol., 14: 1815-1823, 1994.
25. Ogretmen B., Safa A.R.: Expression of the mutated p53 tumor suppressor protein and its molecular and biochemical characterization in multidrug resistant MCF-7/Adr human breast cancer cells. Oncogene, 14: 499-506, 1997.
26. Righetti S.C., Della Torre G., Pilotti S., Menard S., Ottone F., Colnaghi M.I., Pierotti M.A., Lavarino C., Cornarotti M., Oriana S., Bohm S., Bresciani G.L., Spatti G., Zunino F.: A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res., 56: 689-693, 1996.
27. Sancar A.: Mechanisms of DNA excision repair. Science, 266: 1954-1956, 1994.
28. Sjogren S., Inganas M., Norberg T., Lindgren A., Nordgren H., Holmberg L., Bergh J.: The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J. Natl. Cancer Inst., 88: 173-177, 1996.
29. Stewart N., Hicks G.G., Paraskevas F., Mowat M.: Evidence for a second cell cycle block at G2/M by p53. Oncogene, 10: 109-115, 1995.
30. Takenaka I., Morin F., Seizinger B.R., Kley N.: Regulation of the sequence-specific DNA binding function of p53 by protein kinase C and protein phosphatases. J. Biol. Chem., 270: 5405-5411, 1995.
31. Waldman T., Lengauer C., Kinzler K.W., Vogelstein B.: Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature, 381: 713-716, 1996.
32. Werner H., Karnieli E., Rauscher F.J., Le Roith D.: Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc. Natl. Acad. Sci. USA, 93: 8318-8323, 1996.